CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 60 enrolled
Drug / intervention
Aripiprazole IM Depotdrug
Likely dose
Aripiprazole IM Depot 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01552772
NCT01552772Phase 1Completed
CompareCT.gov

An Open-label, Safety and Tolerability Trial of Aripiprazole IM Depot Treatment Initiation in Adult Subjects With Schizophrenia Stabilized on Atypical Oral Antipsychotics Other Than Aripiprazole

Otsuka Pharmaceutical Development & Commercialization, Inc.·interventional·Posted Mar 13, 2012·Updated Oct 10, 2014

In Brief

A Phase 1 clinical trial evaluating Aripiprazole IM Depot for Schizophrenia. Completed, enrolled 60 participants across 12 sites.

Detailed Summary

This study will test the safety of an aripiprazole injection in subjects with schizophrenia that are currently taking oral antipsychotic medication other than aripiprazole. Subjects in this study will receive one injection of aripiprazole and will need to stop taking their other antipsychotic medication two weeks after the injection. The study will last one month. Subjects will be required to come to a clinic for evaluations and drug and urine collection five times during the course of the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMar 13, 2012
Enrollment StartJan 1, 2012
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 14.3 years ago

Interventions

Aripiprazole IM Depotdrug

400 mg intramuscular injection of aripiprazole